------------------------------
OMB APPROVAL
------------------------------
UNITED STATES
SECURITIES AND EXCHANGE COMMISSION
Washington, D.C. 20549
SCHEDULE 13D
INFORMATION TO BE INCLUDED IN STATEMENTS FILED PURSUANT TO
RULE 13d-1(a) AND AMENDMENTS THERETO FILED PURSUANT TO RULE 13d-2(a)
(Amendment No. 1)
Schein Pharmaceutical, Inc.
- --------------------------------------------------------------------------------
(Name of Issuer)
Common Stock, par value $0.01 per share
- --------------------------------------------------------------------------------
(Title of Class of Securities)
806416-10-3
- --------------------------------------------------------------------------------
(CUSIP Number)
Paul Feuerman, Esq. Richard L. Goldberg, Esq.
Senior Vice President and General Counsel Proskauer Rose LLP
Schein Pharmaceutical, Inc. 1585 Broadway
100 Campus Drive New York, NY 10036
Florham Park, NJ 07932 (212)969-3000
(973)593-5500
- --------------------------------------------------------------------------------
(Name, Address and Telephone Number of Person
Authorized to Receive Notices and Communications)
March 1, 2000
- --------------------------------------------------------------------------------
(Date of Event which Requires Filing of this Statement)
If the filing person has previously filed a statement on Schedule 13G to
report the acquisition which is the subject of this Schedule 13D, and is filing
this schedule because of Rule 13d-1(e), 13d-1(f) or 13d-1(g), check the
following box [_].
<PAGE>
CUSIP No. 806416-10-3 SCHEDULE 13D Page 2 of 11 Pages
________________________________________________________________________________
1 NAME OF REPORTING PERSONS
I.R.S. IDENTIFICATION NOS. OF ABOVE PERSONS (ENTITIES ONLY)
Martin Sperber
________________________________________________________________________________
2 CHECK THE APPROPRIATE BOX IF A MEMBER OF A GROUP*
(a) [_]
(b) [X]
________________________________________________________________________________
3 SEC USE ONLY
________________________________________________________________________________
4 SOURCE OF FUNDS*
Not Applicable
________________________________________________________________________________
5 CHECK BOX IF DISCLOSURE OF LEGAL PROCEEDINGS IS REQUIRED
PURSUANT TO ITEMS 2(D) OR 2(E) [_]
________________________________________________________________________________
6 CITIZENSHIP OR PLACE OF ORGANIZATION
United States
________________________________________________________________________________
7 SOLE VOTING POWER
NUMBER OF 1,313,532 shares of Common Stock
SHARES _________________________________________________________________
8 SHARED VOTING POWER
BENEFICIALLY
OWNED BY
_________________________________________________________________
EACH 9 SOLE DISPOSITIVE POWER
REPORTING
656,342 shares of Common Stock
PERSON _________________________________________________________________
10 SHARED DISPOSITIVE POWER
WITH
657,190 shares of Common Stock
________________________________________________________________________________
11 AGGREGATE AMOUNT BENEFICIALLY OWNED BY EACH REPORTING PERSON
1,313,532 shares of Common Stock
________________________________________________________________________________
12 CHECK BOX IF THE AGGREGATE AMOUNT IN ROW (11) EXCLUDES CERTAIN SHARES*
________________________________________________________________________________
13 PERCENT OF CLASS REPRESENTED BY AMOUNT IN ROW (11)
4%
________________________________________________________________________________
14 TYPE OF REPORTING PERSON*
IN
________________________________________________________________________________
*SEE INSTRUCTIONS BEFORE FILLING OUT!
INCLUDE BOTH SIDES OF THE COVER PAGE, RESPONSES TO ITEMS 1-7
(INCLUDING EXHIBITS) OF THE SCHEDULE, AND THE SIGNATURE ATTESTATION.
2
<PAGE>
The Reporting Person hereby amends this Schedule 13D to include the following
information in Item 5.
ITEM 5. INTEREST IN SECURITIES OF THE ISSUER.
On March 1, 2000, the Voting Trust terminated in accordance with its terms and
Mr. Sperber ceased to be the beneficial owner of more than 5% of the Company's
outstanding Common Stock.
As of the date of this amendment to Schedule 13D, Mr. Sperber beneficially owns
1,313,532 shares of Common Stock, or approximately 4% of the Company's
outstanding Common Stock. Of such shares, Mr. Sperber may be deemed to have sole
voting power over 1,313,532 shares of Common Stock, sole dispositive power over
656,342 shares of Common Stock and shared dispositive power over 657,190 shares
of Common Stock.
The 1,313,532 shares of Common Stock beneficially owned by Mr. Sperber consist
of:
(a) 619,290 shares for which Mr. Sperber either is the direct or
indirect beneficial owner or holds in trusts for his family
members' benefit;
(b) 651,475 shares issuable pursuant to the exercise of stock options
that are held by Mr. Sperber and are currently exercisable;
(c) 37,900 shares held in a joint account for Mr. Sperber and his
wife, Ellen Sperber; and
(d) 4,867 shares acquired by Mr. Sperber pursuant to The Retirement
Plan of Schein Pharmaceutical, Inc. & Affiliates and the
Company's 1998 Employee Stock Purchase Plan.
Mr. Sperber has not acquired or disposed of beneficial ownership of any shares
of Common Stock in the past 60 days other than upon the vesting of options and
shares acquired periodically pursuant to The Retirement Plan of Schein
Pharmaceutical, Inc. & Affiliates and the Company's 1998 Employee Stock Purchase
Plan.
SIGNATURE
After reasonable inquiry and to the best of my knowledge and belief, I
certify that the information set forth in this statement is true, complete and
correct.
March 16, 2000 /s/ Martin Sperber
- ----------------------------- -----------------------------------
Date Martin Sperber
3
